UK markets closed
  • FTSE 100

    6,647.80
    -3.08 (-0.05%)
     
  • FTSE 250

    20,986.98
    -309.25 (-1.45%)
     
  • AIM

    1,162.29
    -11.10 (-0.95%)
     
  • GBP/EUR

    1.1587
    -0.0010 (-0.08%)
     
  • GBP/USD

    1.3805
    -0.0089 (-0.64%)
     
  • BTC-GBP

    34,258.23
    -1,617.99 (-4.51%)
     
  • CMC Crypto 200

    943.62
    +0.45 (+0.05%)
     
  • S&P 500

    3,749.02
    -19.45 (-0.52%)
     
  • DOW

    30,873.79
    -50.35 (-0.16%)
     
  • CRUDE OIL

    65.61
    +1.78 (+2.79%)
     
  • GOLD FUTURES

    1,695.70
    -5.00 (-0.29%)
     
  • NIKKEI 225

    28,864.32
    -65.79 (-0.23%)
     
  • HANG SENG

    29,098.29
    -138.50 (-0.47%)
     
  • DAX

    13,951.53
    -104.81 (-0.75%)
     
  • CAC 40

    5,797.68
    -32.97 (-0.57%)
     

​​​​​​​Eckert & Ziegler to Build cGMP Facility for Radiopharmaceutical Services in USA

·3-min read

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Expansion/Miscellaneous
28.01.2021 / 10:13
The issuer is solely responsible for the content of this announcement.

Berlin, 28 January 2021. Eckert & Ziegler is proud to announce that it is expanding its production site in Wilmington just north of Boston, Massachusetts of a new production facility for the contract manufacturing of radiopharmaceuticals. This new cGMP clean room suite will be a 21 CFR 211 compliant, radiopharmaceutical manufacturing facility dedicated to late stage investigational and commercial stage radiopharmaceuticals. Together with our current facilities in Germany, the new U.S. based cGMP facility, will enable Eckert & Ziegler to provide radiopharmaceutical development services to companies looking for US and worldwide contract manufacturing.

"To meet the growing global demand for radiopharmaceutical services involving both imaging and therapy products, we have decided to make this investment. At the moment, a large number of radiopharmaceutical substances from international pharmaceutical companies are in advanced clinical trials, some of them for broad indications such as prostate cancer," explains Dr. Lutz Helmke, member of the Executive Board of Eckert & Ziegler AG and responsible for the Medical segment. "With the new cGMP facility, we offer both regional and global pharmaceutical companies a one-stop service for a variety of radio-pharmaceutical services under cGMP conditions."

Currently, a production facility is being completed at the Wilmington, MA site to manufacture yttrium-90 based radiopharmaceuticals for the treatment of liver cancer. In the future, the company will expand its European production capacity for Lutetium-177 labeled drugs to its U.S. site.

Lutetium-177 is a coveted active ingredient in many new cancer therapy drugs. "Due to the large number of studies in which lutetium-177 is being clinically tested worldwide, we expect an increasing demand for this isotope and related services in the coming years. With our production sites in Europe, Asia and North America, we believe we are ideally positioned to meet this demand," adds Dr. Lutz Helmke.

The new cGMP suite, will enable Eckert & Ziegler to offer complete early development services, including process development and scale-up, CMC manufacturing and packaging, product release and stability programs. The company will thus be able to manufacture products on a clinical scale of phases I, II and III and for commercial use as a radiopharmaceutical contract manufacturer.

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees, is one of the world's largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at various locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com


28.01.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Eckert & Ziegler Strahlen- und Medizintechnik AG

Robert-Rössle-Str.10

13125 Berlin

Germany

Phone:

+49 30 941084-138

Fax:

+49 30 941084-112

E-mail:

karolin.riehle@ezag.de

Internet:

www.ezag.de

ISIN:

DE0005659700

WKN:

565970

Indices:

SDAX

Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

EQS News ID:

1163968


 

End of News

DGAP News Service

show this
show this